Sara E Wobker

University of North Carolina at Chapel Hill
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (26)

Radiotherapy (RT) for prostate cancer has been associated with an increased risk for the development of bladder cancer. We aimed to integrate clinical and genomic data to better understand the development of RT-associated bladder cancer. A retrospective analysis was performed to identify control patients (CTRL; n = 41) and patients with RT-associated bladder cancer ( n = 41). RT- and CTRL-specific features were then identified through integration and analysis of the genomic sequencing data and clinical variables. RT-associated bladder tumors were significantly enriched for alterations in KDM6A and ATM , whereas CTRL tumors were enriched for CDKN2A mutation. Globally, there were an increased number of variants within RT tumors, albeit at a lower variant allele frequency. Mutational signature analysis revealed three predominate motif patterns, with similarity to SBS2/13 (APOBEC3A), SBS5 (ERCC2/smoking), and SBS6/15 (MMR). Poor prognostic factors in the RT cohort include a short tumor latency, smoking status, the presence of the smoking and X-ray therapy mutational signatures, and CDKN2A copy number loss. Based on the clinical and genomic findings, we suggest at least two potential pathways leading to RT-associated bladder cancer: The first occurs in the setting of field cancerization related to smoking or preexisting genetic alterations and leads to the development of more aggressive bladder tumors, and the second involves RT initiating the oncogenic process in otherwise healthy urothelium, leading to a longer latency and less aggressive disease. Significance: Clinicogenomic analysis of radiation-associated bladder cancer uncovered mutational signatures that, in addition to a short tumor latency, smoking, and CDKN2A loss, are associated with a poor outcome. These clinical and genomic features provide a potential method to identify patients with prostate cancer who are at an increased risk for the development of aggressive bladder cancer following prostate RT.

Year:

2025

Mutational characterization of the CTRL and RT cohorts. BAM files corresponding to the FoundationOne sequencing assay were back converted to FASTQ format and aligned to GRCh38. A, The number of alterations per sample was calculated and plotted by variant type (insertions, SNVs, silent, intronic, missense, nonsense, and deletions). Pairwise comparisons between CTRL (gold), RT–short latency (dark blue), and RT–long latency (light blue) tumors were made using the Wilcoxon rank-sum test, with P values listed above their corresponding comparison. B, Histogram of VAF (alternate read count/total read depth) for CTRL (gold), RT–short latency (dark blue), and RT–long latency (light blue) tumors, variants are bin by a frequency of 0.01 (1%). Dashed line represents a VAF of 0.05 (5%). Inset boxplots represent alterations per sample either above or below the 5% VAF threshold and grouped by latency. Pairwise comparisons between CTRL (gold), RT–short latency (dark blue), and RT–long latency (light blue) tumors were made using the Wilcoxon rank-sum test, with P values listed above their corresponding comparison. Boxplots are represented by the IQR and midline at the median. Error bars equal the Q1/Q3 ± 1.5 × IQR. Oncoplots of recurrent mutations occurring above a frequency of 10% in the ( C ) CTRL and ( D ) RT cohorts. Only mutations with a VAF of ≥5% were included. E, Mutation enrichment was performed using the maftools package, and genes with an FDR >0.05 are indicated. Bars to the left of the dashed line represent CTRL vs. RT, with bars to the right of the dashed line indicating significant gene based on a 1 vs. other comparison. F, Comparison of KDM6A mutations between non-RT (TCGA and CTRL) and RT (RT and DFCI) cohorts. WT, wild type.

Year:

2025

Objectives Neoadjuvant chemotherapy (NACT) is recommended for muscle-invasive bladder cancer, and robust treatment response may result in lack of grossly identifiable tumor in the cystectomy specimen. Current gross examination and reporting protocols, however, do not include specific guidance on the approach to these specimens. Methods A Qualtrics survey was disseminated by email and X (formerly Twitter). Responses from pathologists and pathologists’ assistants (PAs) were included. The survey interrogated demographics, practice settings, prevalence of NACT use, approach to gross examination, and reporting practices in the setting of both grossly visible tumor or ulcer bed and the complete absence of a gross lesion. Results Based on 55 respondents’ experience, identifying gross tumor occurred less frequently than tumor or ulcer bed (40% vs 71%). Lack of identification of any gross lesions was estimated to occur in 29% of cases. Gross examination practices were relatively consistent in cases with residual gross tumor or gross tumor bed, with agreement that gross tumor should be submitted as 1 block per centimeter (66%), and tumor or ulcer bed should be submitted in its entirety (97%). Gross examination practices appeared more varied when no gross lesions were identified. Overall, most responders stated they “definitely” or “maybe” support a standardized gross examination (89%) and reporting (96%) protocol. Conclusions With the increased use of NACT, lack of any gross lesion leads to inconsistent gross examination techniques. This study provides insight into the current approach to examination of post-NACT cystectomies and suggests that a desire exists among pathologists and pathologists’ assistants for more standardized practice.

Year:

2024

Supplementary Table S7. Hazard ratios and 95% confidence intervals for associations between immune cell types and risk of prostate cancer progression in the UNC CSC, overall and stratified by ERG expression.

Year:

2024

Supplementary Figure S4. Boxplots comparing gene expression-based immune cell types in men with high tumor aggressiveness reporting any vs. no vigorous recreational activity. A. Gleason score ≥4 + 3. B. Clinical stage III-IV.

Year:

2024

Supplementary Table S6. Hazard ratios and 95% confidence intervals for associations between histologic inflammation and risk of prostate cancer progression in the pooled study, overall and stratified by ERG expression.

Year:

2024

Supplementary Figure S3. Boxplots comparing gene expression-based immune cell types in men with low tumor aggressiveness reporting any vs. no vigorous recreational activity. A. Gleason score ≤3 + 4. B. Clinical stage I-II.

Year:

2024

Supplementary Figure S1. Correlation plot for the relationship of gene expression-based with histological measures of immune infiltrate in prostate cancer. Gene expression-based measures include B cells, T cells, Th cells, Tfh, Treg, exhausted CD4 T cells, CD8 T cells, exhausted CD8 T cells, NK cells, neutrophils, eosinophils, macrophages and immune signature. Histological measures include TILs% tumor gland, TILs% tumor stroma and neutrophils grade tumor. Spearman’s correlation. *P

Year:

2024

Supplementary Table S8. Hazard ratios and 95% confidence intervals for associations between immune cell types and risk of prostate cancer progression in the FASTMAN, overall and stratified by ERG expression.

Year:

2024

Supplementary Figure S2. Concordance between QuPath algorithm and pathologist and reproducibility across times. A-D, Bland-Altman plots showing differences in TILs% between QuPath algorithm and manual counting in (A) stroma of tumor core, (B) gland of tumor core, (C) stroma of tumor adjacent, and (D) gland of tumor adjacent. E-H, Differences of TILs% one year later by same performer using QuPath. Concordance by ICC values: ≤0.20, poor; 0.21 to 0.40, fair; 0.41 to 0.60, moderate; 0.61 to 0.80, good, and ≥0.81, excellent. CI, confidence interval; ICC, intraclass correlation coefficient; TILs, tumor infiltrating lymphocytes.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (13)

Katherine Hoadley

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Melissa LaBonte

Senior Lecturer

The Queen's University Belfast

UNITED KINGDOM
View details

William Y. Kim

Professor

University of North Carolina

UNITED STATES
View details

Tracy Rose

Assistant Professor

University of North Carolina

UNITED STATES
View details

Stephanie Craig

The Queen's University Belfast

UNITED KINGDOM
View details

Lanshan Huang

Queen's University Belfast

UNITED KINGDOM
View details

suneil jain

Queen's University Belfast

UNITED KINGDOM
View details

Krishna Kanchi Kanchi

National Institutes of Health

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Jeffrey Damrauer

Assistant Professor

University of North Carolina

UNITED STATES
View details

Matthew D. Galsky

Radboud University Medical Center

NETHERLANDS
View details

Stephen Finn

Associate Professor

Trinity College Dublin School of Medicine

IRELAND
View details

David Corcoran

Assistant Professor

University of North Carolina

UNITED STATES
View details